Lima Urban Minority Alcohol Drug Abuse Outreach Program

Lima Urban Minority Alcohol Drug Abuse Outreach Program is a SAMHSA-registered addiction-treatment facility in New York, NY. The facility's programming is outpatient (Outpatient, MAT), not residential. This page frames the questions that matter most when evaluating a specific program — the ones that separate useful candidates from marginal ones.

Care levels at Lima Urban Minority Alcohol Drug Abuse Outreach Program

Lima Urban Minority Alcohol Drug Abuse Outreach Program is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. ASAM Criteria 4e is the benchmark framework for matching patients to appropriate intensity. Most major payer medical-necessity documents reference it. An outside ASAM-aligned assessment, prior to admission, is the protection against misplacement.

Insurance and payment

Lima Urban Minority Alcohol Drug Abuse Outreach Program accepts Medicaid — which is consequential because facilities that accept Medicaid tend to have the broadest patient populations and the most developed public-sector relationships, though reimbursement structures mean program intensity sometimes differs from commercial-focused centers. Before admission, request a written Verification of Benefits from the facility's utilization-review team. Verbal VOB is where most post-admission cost-sharing disputes originate. Written documentation settles them.

Before you call

The operational due diligence on Lima Urban Minority Alcohol Drug Abuse Outreach Program comes down to three documents: ASAM-aligned level-of-care documentation matching independent clinical assessment, written Verification of Benefits for your specific plan product, written MAT policy. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.